Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC.

Clin Cancer Res. 2013 May 15;19(10):2723-33. doi: 10.1158/1078-0432.CCR-12-2986.

2.

Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.

Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N, Ishida T.

Breast Cancer Res. 2015 Sep 4;17:124. doi: 10.1186/s13058-015-0632-x.

3.

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, Sieuwerts AM, Span PN, Sweep FC, Linderholm BK, Mangia A, Paradiso A, Dirix LY, Van Laere SJ, Luider TM, Martens JW, Foekens JA, Umar A.

J Natl Cancer Inst. 2014 Feb;106(2):djt376. doi: 10.1093/jnci/djt376.

4.

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.

Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.

Breast Cancer Res. 2014 Aug 8;16(4):406. doi: 10.1186/s13058-014-0406-x.

5.

BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.

Bouchalova K, Svoboda M, Kharaishvili G, Vrbkova J, Bouchal J, Trojanec R, Koudelakova V, Radova L, Cwiertka K, Hajduch M, Kolar Z.

Tumour Biol. 2015 Jun;36(6):4243-52. doi: 10.1007/s13277-015-3061-7.

PMID:
25616695
6.

A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.

Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L.

Clin Cancer Res. 2015 Mar 1;21(5):1207-14. doi: 10.1158/1078-0432.CCR-14-2011.

7.

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2015 Dec 18;10(12):e0144359. doi: 10.1371/journal.pone.0144359. Erratum in: PLoS One. 2016;11(7):e0159123.

8.

Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.

Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S552-8. doi: 10.1245/s10434-015-4600-6.

PMID:
25968619
9.

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.

Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SY.

Ann Oncol. 2013 Nov;24(11):2801-7. doi: 10.1093/annonc/mdt277.

10.

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.

Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K.

Oncotarget. 2014 Mar 15;5(5):1174-84.

11.

Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.

Lee HJ, Lee JJ, Song IH, Park IA, Kang J, Yu JH, Ahn JH, Gong G.

Breast Cancer Res Treat. 2015 Jun;151(3):619-27. doi: 10.1007/s10549-015-3438-8.

PMID:
26006068
12.

Prognostic value of ERBB4 expression in patients with triple negative breast cancer.

Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH, Im YH.

BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.

13.

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.

Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A.

PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403.

14.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Clin Cancer Res. 2016 Feb 15;22(4):905-14. doi: 10.1158/1078-0432.CCR-15-0610.

PMID:
26240276
15.

MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.

Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, Chang G, Li X, Li Q, Wang S, Wang W.

PLoS One. 2014 May 2;9(5):e96228. doi: 10.1371/journal.pone.0096228.

16.

Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.

Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ.

J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):262-5. doi: 10.1007/s11596-013-1108-9.

PMID:
23592141
17.

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.

Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM.

BMC Med. 2015 Dec 18;13:303. doi: 10.1186/s12916-015-0540-z.

18.

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT.

Clin Cancer Res. 2013 Oct 1;19(19):5533-40. doi: 10.1158/1078-0432.CCR-13-0799.

19.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL.

Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286.

20.

A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.

Park YH, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH.

Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233.

Items per page

Supplemental Content

Support Center